R1 RCM Inc

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

R1 RCM Inc (RCM) posts strong Q4 results, eyes Cloudmed growth

R1 RCM Inc (RCM) delivered robust financial performance in Q4 2022, focusing on operational excellence, technology investments, and customer engagement. Challenges include integration efforts and seasonality affecting incentive fees. The company is poised for growth with opportunities in Cloudmed expansion and AI utilization.

R1 RCM Inc (RCM) reports strong Q1 results and growth opportunities

R1 RCM Inc (RCM) delivered strong Q1 results, with a focus on operational improvements, robust Cloudmed growth, and positive financial outlook for 2023.
The company showcased resilience in stable patient self-pay trends, improving payer reimbursement timelines, and strategic capacity for onboarding new NPR, positioning itself for continued success.
Challenges include industry financial pressures, sustaining growth in legacy business, and managing operational costs effectively, requiring strategic adaptation and continuous innovation.
Opportunities lie in pipeline visibility for deals, sequential EBITDA growth, integration of Cloudmed capabilities, and strategic onboarding plans, offering avenues for expansion and profitability.

R1 RCM Inc reports robust Q2 earnings, eyes growth opportunities

R1 RCM Inc's Q2 performance was strong, with a focus on technology and operational enhancements. Challenges include revenue adjustments and workforce implications of automation. Opportunities lie in improved payer dynamics and growth through physician market focus and cross-selling.

R1 RCM Inc reports robust Q3 performance and eyes growth

R1 RCM Inc's Q3 earnings call highlighted strong financial performance, strategic priorities, and challenges in pediatric contracts and integration issues.
The company's focus on revenue optimization, leveraging technology, and partnership with Microsoft positions it well for growth opportunities within the customer base and offshoring initiatives.
While facing challenges in deal timings and debt repayment, R1 RCM Inc's emphasis on operational metrics, customer relationships, and workforce management presents avenues for continued success and industry leadership.

R1 RCM Inc reports robust Q4 earnings, eyes growth opportunities

R1 RCM Inc's Q4 2023 earnings call highlighted strong financial performance, strategic objectives for 2023, and a confident outlook for sustainable growth and shareholder value creation.
The company's emphasis on customer-centricity, AI integration, and operational efficiency underscores its strengths in revenue growth and market positioning.
While facing challenges in credit allowances and customer health, R1 RCM Inc aims to leverage opportunities in reduced costs, synergies from acquisitions, and strategic sales to drive future growth.

R1 RCM reports resilient Q1 performance post-cyberattack, eyes growth

R1 RCM showcased resilience in Q1 2024 despite the Change Healthcare cyberattack, focusing on growth strategies, operational excellence, and technology innovation.
The company faces challenges from the cyberattack impact on KPIs and vendor changes but sees opportunities in the managed care environment and customer engagement.
Overall, R1 RCM remains optimistic about transforming the industry through technology and expertise, with a strong market demand for its solutions.

R1 RCM Inc reports robust Q2 earnings amidst cyberattack challenges

R1 RCM Inc's Q2 2024 earnings call showcased strong financial performance, operational resilience in the face of cyberattacks, and a strategic focus on growth initiatives. The company faces challenges related to pending transactions and cyberattack impacts but sees opportunities in expanding its platform and leveraging technology for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MURRAY, Utah, April 07, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that Project Roadrunner Parent Inc., a wholly owned subsidiary of R1, has publicly filed a registration statement on Form S-4 relating to its previously announced proposed acquisition of Cloudmed, a leader in Revenue Intelligence™ solutions for healthcare providers.

R1 RCM Announces Filing of Registration Statement on Form S-4 Related to Proposed Acquisition of Cloudmed

Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2022) - Investor protection firm Kaskela Law LLC announces that is investigating the Board of Directors of R1 RCM Inc. (NASDAQ: RCM) on behalf of the company's stockholders.On January 10, 2022, R1 RCM announced that it had entered into a definitive agreement to acquire Cloudmed in an all-stock transaction valued at $4.1 billion. According to the announcement, R1 RCM is expected to issue approximately 138 million shares of...

INVESTIGATION ALERT: Kaskela Law LLC Announces Stockholder Investigation of R1 RCM Inc. (RCM) in Connection with Recent Merger Announcement

R1 RCM's (RCM) CEO Joe Flanagan on Q4 2021 Results - Earnings Call Transcript

R1 RCM Inc. (RCM) delivered earnings and revenue surprises of 10% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

R1 RCM Inc. (RCM) Q4 Earnings Top Estimates

MURRAY, Utah, Feb. 17, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months and year ended December 31, 2021.

R1 RCM Reports Fourth Quarter and Full Year 2021 Results

MURRAY, Utah, Feb. 14, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 1:00 pm ET.

R1 RCM to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Best in KLAS® designation validates R1 as a market leader in revenue cycle services for physician groups Best in KLAS® designation validates R1 as a market leader in revenue cycle services for physician groups

R1 RCM Ranked #1 by KLAS for Ambulatory RCM Services Second Year in a Row

MURRAY, Utah, Feb. 07, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), today announced that Alex Mandl informed the company he will not stand for re-election to the R1 board of directors at its next annual meeting of stockholders. Mr. Mandl was elected to the R1 board of directors in 2013 and has served as lead director since 2018 and chair of the audit committee since 2015.

R1 Announces Alex Mandl Will Not Stand for Re-Election to R1 Board of Directors

MURRAY, Utah, Jan. 31, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months and full year ended December 31, 2021 before market open on Thursday, February 17, 2022.

R1 RCM to Release Fourth Quarter 2021 Results on February 17

R1 received 100% ranking and was named one of the Best Places to Work for LGBTQ+ Equality R1 received 100% ranking and was named one of the Best Places to Work for LGBTQ+ Equality

R1 Earns Top Score in Human Rights Campaign's 2022 Corporate Equality Index

Hiring of world-class talent, expansion of automation capabilities and strategic acquisitions fuel R1's mission to make healthcare simpler Hiring of world-class talent, expansion of automation capabilities and strategic acquisitions fuel R1's mission to make healthcare simpler

R1's Growth Momentum Accelerates Investment in Technology

Zynga

NEW YORK, Jan. 16, 2022 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Apria, Inc. (NASDAQ: APR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Owens & Minor, Inc. for $37.50 per share in cash. If you are an Apria shareholder, click here to learn more about your rights and options.

Halper Sadeh LLP Investigates APR, RCM, ZNGA; Shareholders are Encouraged to Contact the Firm

R1 RCM Inc. (NASDAQ: RCM) announced it is buying Cloudmed for $4.1 billion. These are the details.

Why R1 RCM (RCM) Is Buying Cloudmed For $4.1 Billion

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of R1 RCM Inc. (NASDAQ: RCM) and Cloudmed is fair to RCM shareholders. Upon closing of the merger, R1 shareholders are expected to own approximately 70% of the combined company on a fully diluted basis while Cloudmed equity holders are expected to own approximately 30%. Halper Sadeh encourages RCM shareholders to click here to learn more about their legal rights and options or con

RCM Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of R1 RCM Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – RCM

Advances Integrated Technology Strategy Through Enhanced Revenue Intelligence and Expanded Automation Opportunity

R1 RCM to Acquire Cloudmed, Creating the Strategic Revenue Partner for Healthcare Providers

MURRAY, Utah, Dec. 31, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 11:15 am ET.

R1 RCM to Present at the 40th Annual J.P. Morgan Healthcare Conference

VisitPay to offer a seamless and complete payment experience for Adventist Health patients expanding the reach of R1's Entri™ platform VisitPay to offer a seamless and complete payment experience for Adventist Health patients expanding the reach of R1's Entri™ platform

Adventist Health Selects R1 as Patient Billing Partner in its Quest for Consumer Excellence

R1 RCM Inc. (RCM) CEO Joe Flanagan on Q3 2021 Results - Earnings Call Transcript

R1 RCM Inc. (RCM) delivered earnings and revenue surprises of -37.50% and 1.83%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

R1 RCM Inc. (RCM) Q3 Earnings Miss Estimates

MURRAY, Utah, Nov. 02, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2021.

R1 RCM Reports Third Quarter 2021 Results

Company has completed prior $50 million repurchase program Company has completed prior $50 million repurchase program

R1 RCM Announces $200 Million Share Repurchase Program

MURRAY, Utah, Oct. 25, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, announced today that American Physician Partners (APP), a recognized leader in emergency medicine, hospital medicine and intensive care management services, with more than 150 hospital and system partnerships, has extended its revenue cycle management (RCM) partnership with R1 until 2031.

American Physician Partners Announces Revenue Cycle Partnership Extension with R1 to Support Its Continued Growth in Emergency Medicine Market

MURRAY, Utah, Oct. 12, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended September 30, 2021 before market open on Tuesday, November 2, 2021.

R1 RCM to Release Third Quarter 2021 Results on November 2

MURRAY, Utah, Aug. 12, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the appointment of Agnes Bundy Scanlan, president of The Cambridge Group LLC, to the company's board of directors, effective August 11, 2021.

R1 Announces Appointment of Agnes Bundy Scanlan to Board of Directors

R1 RCM Inc. (RCM) CEO Joe Flanagan on Q2 2021 Results - Earnings Call Transcript

News for R1 RCM Inc Stock (RCM)